Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$4.6 million.

  • Spyre Therapeutics' Cash from Financing Activities fell 13633.02% to -$4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.8 million, marking a year-over-year decrease of 3642.68%. This contributed to the annual value of $410.9 million for FY2024, which is 1380.01% up from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Cash from Financing Activities is -$4.6 million, which was down 13633.02% from $731000.0 recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Cash from Financing Activities ranged from a high of $225.6 million in Q4 2024 and a low of -$12.5 million during Q3 2023
  • Its 5-year average for Cash from Financing Activities is $42.8 million, with a median of $360000.0 in 2024.
  • Data for Spyre Therapeutics' Cash from Financing Activities shows a peak YoY increase of 204517500.0% (in 2023) and a maximum YoY decrease of 953923.08% (in 2023) over the last 5 years.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Cash from Financing Activities stood at $80000.0 in 2021, then tumbled by 110.0% to -$8000.0 in 2022, then surged by 2045175.0% to $163.6 million in 2023, then skyrocketed by 37.89% to $225.6 million in 2024, then crashed by 102.06% to -$4.6 million in 2025.
  • Its Cash from Financing Activities stands at -$4.6 million for Q3 2025, versus $731000.0 for Q2 2025 and $125000.0 for Q1 2025.